- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00152061
The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral Regimens
18 juni 2013 uppdaterad av: Stanford University
The Role of 3TC/FTC in Partially Suppressive Antiretroviral Regimens: The Switch Study
In this study the researchers will be enrolling patients who are failing their current antiretroviral regimen who also have resistance to 3TC or FTC.
Patients will have their current antiretroviral regimen changed based on resistance testing and also be randomly assigned to either include, or not include 3TC/FTC in this new regimen.
The purpose of the research is to investigate whether the change in therapy results in a decrease in the amount of virus particles and an increase in the CD4 cell count.
In addition the researchers are investigating the relationship between the existence of resistance and the rate of decrease in viral load, and also to determine if continuing 3TC/FTC (despite being resistant to the medications) has any effect on the rate of decrease of viral load, or effect on CD4 counts.
Studieöversikt
Detaljerad beskrivning
In this randomized, open-label, controlled trial, HIV-infected patients who are failing 3TC/FTC-containing highly active antiretroviral therapy, (HAART), will be offered individual treatment selection based on best clinical judgment and genotypic HIV-RNA resistance analysis.
Patients who meet entry criteria will first be randomized to either continue or discontinue 3TC/FTC while they remain on their current therapy.
HIV-1 viral load will be measured 4 times over a period of 14 days to determine the virologic response to this change.
At day 14, each patient's regimen will be optimized to a new combination based on a genotype test taken at study entry.
Patients will then start on the new salvage regimen, including or not including 3TC/FTC based on their initial randomization.
Additional HIV-1 viral load measurements will be obtained to determine the virologic response to the new salvage regimen over 24 weeks.
Studietyp
Interventionell
Inskrivning
40
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
California
-
San Jose, California, Förenta staterna, 95128
- Santa Clara Medical Center, PACE Clinic
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- HIV-1 seropositive patients >= 18 years of age
- Willingness and ability to understand and sign a written informed consent and comply with the protocol procedure
- Prior treatment with nucleoside reverse transcriptase inhibitors (NRTI's), non-nucleoside reverse transcriptase inhibitors (NNRTI's) and protease inhibitor (PI)-containing regimens
- On a stable PI and 3TC or FTC -containing regimen for >= 2 months
- Plasma HIV-1 RNA >5000 copies/ml
- CD4 >100
- Documented M184V or I on genotype within 3 months of study entry
- At least 3 PI-associated resistance mutations on genotype within 3 months of study entry, (including known resistance mutations at codons 10, 30, 46, 50, 54, 71, 82, 84, and 90)
Exclusion Criteria:
- In the opinion of the investigator a patient that is either unwilling or unable to be adherent to antiretroviral drugs
- Requirement for concomitant treatment with medicines that interfere with the therapy prescribed in the study
- Patients who have never taken 3TC or FTC, or with no prior documentation of the M184V mutation
- Active hepatitis B infection
- Vaccination within 2 weeks of entering the study
- An acute opportunistic illness within 4 weeks of entering the study; chronic infections will not be excluded
- Use of immunomodulatory medications such as IL-2
- Planned use of enfuvirtide, (T20) in salvage regimen, (in T20 naïve subjects)
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vad mäter studien?
Primära resultatmått
Resultatmått |
---|
To evaluate the role of lamivudine, (3TC), and emtricitabine, (FTC), in salvage regimens in patients with prior 3TC/FTC use, documented resistance to 3TC/FTC, and ongoing viremia as assessed by:
|
Impact on the initial rate of change in HIV-1 viral load after removing 3TC/FTC from the failing regimen, and
|
Overall change from baseline in HIV-1 viral load at 24 weeks (HIV-VL AUC 24 wks).
|
Sekundära resultatmått
Resultatmått |
---|
To evaluate the impact of continued versus discontinued 3TC/FTC on the prevalence, frequency and dynamics of the M184V/I amino acid substitution over 24 weeks.
|
To determine the proportion of patients failing and/or not responding to therapy after 24 weeks as defined by failure to achieve HIV-1 viral load less than 400 copies/ml and/or less than 50 copies/ml
|
To assess the changes from baseline in absolute CD4 (and CD8) cell counts at 24 weeks.
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Huvudutredare: Andrew Zolopa, MD, Stanford University
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 januari 2005
Avslutad studie (Faktisk)
1 augusti 2005
Studieregistreringsdatum
Först inskickad
8 september 2005
Först inskickad som uppfyllde QC-kriterierna
8 september 2005
Första postat (Uppskatta)
9 september 2005
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
19 juni 2013
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
18 juni 2013
Senast verifierad
1 juni 2013
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 74009
- IRB protocol 74009
- SPO number 25036
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på HIV-infektioner
-
Institut PasteurRekrytering
-
Duke UniversityAvslutadCentral Line-associated Bloodstream Infection (CLABSI)Förenta staterna
-
Catholic University of the Sacred HeartAvslutadCentral Line-associated Bloodstream Infection (CLABSI)
-
The University of Texas Health Science Center,...EurofinsAvslutadOdontogen Deep Space Neck InfectionFörenta staterna
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekryteringCentral Line-associated Bloodstream Infection (CLABSI)Nederländerna
-
University of MalayaTeleflexRekryteringCLABSI - Central Line Associated Bloodstream InfectionMalaysia
-
Johns Hopkins UniversityAvslutadCLABSI - Central Line Associated Bloodstream InfectionFörenta staterna
-
National Taiwan University Hospital Hsin-Chu BranchAvslutadCentral Line-associated Bloodstream Infection (CLABSI)
-
National Taiwan University HospitalAvslutadCentral Line-associated Bloodstream Infection (CLABSI)Taiwan
-
Boston Children's HospitalSterileCare Inc.Anmälan via inbjudanCentral Line komplikation | Central Line-associated Bloodstream Infection (CLABSI)Förenta staterna
Kliniska prövningar på 3TC and FTC
-
Juan A. ArnaizOkänd
-
International Antiviral Therapy Evaluation CenterGilead SciencesAvslutad
-
Fundacion SEIMC-GESIDAAvslutad
-
The HIV Netherlands Australia Thailand Research...National Health Security Office, Thailand; Swiss HIV Cohort StudyAvslutad
-
International Maternal Pediatric Adolescent AIDS...National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy...AvslutadHIV-sjukdomFörenta staterna, Puerto Rico, Argentina, Brasilien, Thailand
-
ANRS, Emerging Infectious DiseasesAvslutadHIV-2-infektionElfenbenskusten, Burkina Faso, Senegal, Togo
-
Prism Health North TexasMerck Sharp & Dohme LLCIndragenFetma | Metaboliskt syndrom | Förändringar i kroppsvikt | Humant immunbristvirus | Fasta | Minoritetshälsa | KONST | BMDFörenta staterna
-
Pedro CahnMerck Sharp & Dohme LLCOkändKronisk infektion med HIVArgentina
-
Mahidol UniversityOkänd
-
University of California, San FranciscoBristol-Myers SquibbAvslutadHIV-infektioner | Hepatit BFörenta staterna